Earnings Releases·Nov 3, 2026, 8:10 AM ET

Precision BioSciences — Q3 2026 Earnings Summary

Q3 2026 net loss narrowed to $7.6 million ($0.28/share) from $21.8 million ($1.84/share) in Q3 2025, driven by a $12.7 million non-cash gain on warrant liability; R&D expenses decreased to $12.7 million from $13.4 million, while cash and equivalents declined to $108.0 million from $137.2 million at year-end 2025.
Management projects cash runway through 2028, supported by an available at-the-market facility, enabling key clinical milestones including initial safety data for FUNCTION-DMD by year-end 2026 and an ELIMINATE-B data presentation at AASLD in November 2026.
Clinical progress includes dosing the first patient in the Phase 1/2 FUNCTION-DMD study, advancing ELIMINATE-B with expanded cohorts, and completing dosing for the ECUR-506 OTC-HOPE trial which showed a 57% reduction in hyperammonemic events.
Strategic partnerships yielded positive outcomes for Azer-cel, with TG Therapeutics reporting stable or improved disability scores in 89% of MS participants and Imugene Limited achieving 81-86% overall response rates in lymphoma cohorts, alongside FDA written guidance on the registrational pathway for the cancer program.